Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loratadine divided dosing versus once-daily dosing for histamine skin response
ACTRN12609000702213Phase 2Completed
- Sponsor
- AFT Pharmaceuticals
- Start
- Sep 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of loratadine in allergic rhinitis (AR) (2 arms), sponsored by AFT Pharmaceuticals. Primary endpoint: Area under the curve of histamine-induced wheal after skin prick test. Started Sep 2009; status: completed.
02
Drugs
loratadine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ACTRN12609000702213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000702213.